Azalea Therapeutics
Berkeley
About Azalea Therapeutics
Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering of these cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $100.0M
- Funding stage: Early Stage Venture
- Last round: Seed (Nov 2025)
- Website: azaleatx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Information Technology, Medical, Product Research
Social Profiles
Canonical: https://fsome.com/organization/azalea-therapeutics-10448 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.